This procedural win removes a near-term distraction for Regeneron, keeping the patent case on its current track. Traders should watch for upcoming summary judgment or claim construction rulings, which could materially shift the risk profile for Eylea biosimilar competition from Amgen's Pavblu.
Price Chart
Executive Summary
The court denied Amgen's motion to remand the aflibercept (Eylea) patent litigation back to the Central District of California, keeping the MDL in the Northern District of West Virginia. This is a procedural win for Regeneron, preserving the court's familiarity with the patents and avoiding a restart in a new forum. The ruling maintains the current litigation trajectory, which has already seen all other defendants settle, leaving Amgen as the sole remaining defendant in the MDL.
Court Ruling Details
Key Facts
- Amgen's motion for suggestion of remand was DENIED.
- The MDL (1:24-MD-3103) concerns Regeneron's biologic Eylea (aflibercept) patents.
- All other defendants in the MDL have settled, leaving only Amgen.
- The court cited its familiarity with the case and the inefficiency of remand as reasons for denial.
- The ruling was issued by Chief Judge Thomas S. Kleeh on August 11, 2026.
Financial Impact
No monetary damages awarded or quantified in this procedural ruling. The ruling preserves the current litigation forum, avoiding potential delays and costs of a transfer.
Risk Factors
- The underlying patent infringement case against Amgen remains unresolved and could result in adverse findings.
- Amgen may appeal this procedural ruling, though the standard for interlocutory appeal is high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2ac00a9fd8-REGN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | — | awaiting T+20 | — | — |
Sep 3, 2026 29d ago | Insider Cluster | $843.47 $735.20 | ▼ −12.84% | ▼ −11.65% | $735.20 (−12.84%) |
Aug 24, 2026 5w ago | Court Ruling | $828.50 $803.90 | ▼ −2.97% | ▼ −4.28% | $735.20 (−11.26%) |
Aug 20, 2026 6w ago | Press Release | $826.64 $784.85 | ▼ −5.06% | ▼ −5.06% | $735.20 (−11.06%) |
Aug 12, 2026 7w ago | Insider Cluster | $797.99 $793.26 | ▼ −0.59% | ▲ +1.30% | $735.20 (−7.87%) |
Aug 11, 2026 7w ago | Court Ruling | $797.00 $807.65 | ▲ +1.34% | ▲ +2.40% | $735.20 (−7.75%) |
Jul 30, 2026 9w ago | 8-K | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 30, 2026 9w ago | Press Release | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 27, 2026 9w ago | Press Release | $695.18 $833.56 | ▼ −19.91% | ▼ −16.52% | $735.20 (−5.76%) |
Jul 17, 2026 11w ago | Press Release | $676.69 $800.70 | ▲ +18.33% | ▲ +13.88% | $735.20 (+8.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access